Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 385-390

  Bottini, A ^a   Berruti, A ^b   Bersiga, A ^a   Brunelli, A ^a   Brizzi, M P ^b   Di Marco, B ^a   Cirillo, F ^a   Tampellini, M ^b   Bolsi, G ^a   Aguggini, S ^a   Betri, E ^a   Filippini, L ^a   Bertoli, A ^a   Alquati, P ^a   Dogliotti, L ^b  

^a Azienda Ospedaliera   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Breast cancer; Ki67; Primary chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; ONCOPROTEIN; TAMOXIFEN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 13144253082     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.385     Document Type: Article

References (31)

1. Pawlicki M, Skolyszewki J and Brandys A: Results of combined treatment of patients with locally advanced breast cancer. Tumori 69: 249-253, 1983.
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans De Yoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G and Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990.
3. Mauriac L, Durand M, Avril A and Dihuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 12: 347-354, 1991.
4. Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E, Vilcoq J, Durand JC and Pouillart P: Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27: 1668-1671, 1991.
5. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Di Marco B, Cirillo F, Bolsi G, Bertoli G, Alquati P and Dogliotti L: Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996.
6. Giralt E, Vilcoq J, Durand JC and Pouillart P: Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27: 1668-1672, 1991.
7. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I and Ford HT: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552, 1995.
8. Bélembaogo E, Feillel V, Chollet P, Curé H, Verrelle P, Kwiatowsky F, Achard JL, Le Bouedec G, Chassagne J, Bignon YJ, De Latour M, Lafaye C and Dauplat J: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896-900, 1992.
9. Fischer B, Brown A, Mamounas EP, Wieand S, Fisher E, Robidoux A, Margolese R, Cruz A, Wickerham DL and Wolmark N: Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997.
10. Fischer B and Mamounas EP: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537-540, 1995.
11. Paridaens RJ and Piccart M: Chemo-hormonal treatment of breast cancer: The state of the art. In: Growth factors and Oncogenes in Breast Cancer. Sluyser M (ed). Health Science Series. Ellis Horwood, Chichester, pp 193-206, 1987.
12. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three? Breast Cancer Res Treat 3: 117-127, 1983.
13. Gelber R, Cole BF, Goldhirsch A, Carsten R, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO and Seyelda P: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted survival. Lancet 347: 1066-1071, 1996.
14. Goldhirsch A and Gelber RD: Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV. Rec Results Cancer Res 115: 153-162, 1989.
15. Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D and Dogliotti L: Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. Anticancer Res 17: 2763-2768, 1997.
16. McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Arch Pathol Lab Med 109: 716-721, 1985.
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
18. Norusis MJ: SPSS/PC+ Base manual for the IBM PC/XT/AT and PS/2. SPSS Inc., Chicago, 1988.
19. Bonadonna G, Valagussa P, Molinterni A, Zambetti M and Brambilla C: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995.
20. Jordan VC, Wolf MF, Mirecki DM, Whitford DA and Welshons WD: Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci 26: 97-152, 1988.
21. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S and Sigurdsson H: erbB2 amplification is associated with tamoxifen resistance in steroid-positive breast cancer. Cancer Lett 81: 137-144, 1994.
22. Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM and Nordenskjod B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 2185-2190, 1995.
23. Silvestrini R, Daidone MG and Costa A: Cell kinetics of solid tumors with time and its clinical implication. Tumori 75: 367-372, 1989.
24. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G and Bonadonna G: Cell kinetics as a prognostic indicator in node negative breast cancer. Eur J Cancer 25: 1165-1171, 1989.
25. 3H-thymidine labeling as a prognostic indicator in node positive breast cancer. J Clin Oncol 8: 1-6, 1990.
26. Railo M, Nordling S, von Bogulawsky K, Leivonen M, Kyllonen L and von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579-583, 1993.
27. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B and Veronesi U: Biologic and clinicopatologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697-704, 1995.
28. Daidone MG, Silvestrini R, Valentinis B, Ferrari L and Bartoli C: Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer 47: 380-383, 1991.
29. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, Baldini E, Giannessi PG and Conte PF: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311-318, 1994.
30. Ellis PA, Salter F, Burton S, Makris A, Smith IE, Powles T and Dowsett M: Oestrogen receptor and Ki67 status in breast carcinomas following primary chemoendocrine therapy. Eur J Cancer 31A: 143-144, 1995.
31. Clarke RB, Laidlaw IJ, Jones LJ, Howell A and Anderson E: Effect of tamoxifen in Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993.